Literature DB >> 15277469

Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats.

Zai-Long Chi1, Seiji Hayasaka, Xue-Yun Zhang, Yoriko Hayasaka, Hu-Shan Cui.   

Abstract

PURPOSE: To investigate effects of rolipram, an inhibitor of type 4 phosphodiesterase, on lipopolysaccharide (LPS)-induced uveitis in Wistar rats.
METHODS: A total of 100 microg LPS was injected into the rat footpad. Rolipram (Wako Pure Chemical, Osaka, Japan) was injected intraperitoneally 30 minutes before administration of LPS. Levels of intracameral protein, cells, E-selectin, tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and nitrite were determined. E-selectin, TNF-alpha, IL-6, and inducible nitric oxide synthase (iNOS) mRNAs and immunohistochemical reactivity of nuclear factor (NF)-kappa B and TNF-alpha were also examined in the iris-ciliary body.
RESULTS: After LPS injection, intracameral protein and cells increased from 18 to 30 hours later. Rolipram, however, inhibited elevation of protein and cells. After LPS injection, mRNA levels of E-selectin, TNF-alpha, and IL-6 in the iris-ciliary body increased 3 hours later, and iNOS mRNA increased 6 hours later. Elevation of mRNA levels for E-selectin, TNF-alpha, and IL-6 was inhibited by rolipram. After LPS injection, intracameral TNF-alpha and IL-6 levels increased 4 to 6 hours later, and nitrite levels increased 14 to 20 hours later. Elevation of TNF-alpha and IL-6 levels was decreased by rolipram. Rolipram did not affect iNOS mRNA and nitrite levels. Immunoreactivity of NF-kappa B was strong 1 hour after LPS injection, and was decreased by rolipram. Immunoreactivity of TNF-alpha was strong 4 hours after LPS injection and was decreased by rolipram.
CONCLUSIONS: NF-kappa B translocation and expression of E-selectin, TNF-alpha, and IL-6 are involved in the pathogenesis of LPS-induced uveitis and are inhibited by rolipram. The inhibitory effect of rolipram in uveitis may be independent of iNOS synthesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15277469     DOI: 10.1167/iovs.03-1373

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  The PDE4 inhibitor rolipram prevents NF-kappaB binding activity and proinflammatory cytokine release in human chorionic cells.

Authors:  Roxane Hervé; Thomas Schmitz; Danièle Evain-Brion; Dominique Cabrol; Marie-Josèphe Leroy; Céline Méhats
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

2.  Effect of N-acetylcysteine on lipopolysaccharide-induced uveitis in rats.

Authors:  Xue-Yun Zhang; Seiji Hayasaka; Yoriko Hayasaka; Hu-Shan Cui; Zai-Long Chi
Journal:  Jpn J Ophthalmol       Date:  2007-02-09       Impact factor: 2.447

3.  Expression of TLR4-MyD88 and NF-κB in the iris during endotoxin-induced uveitis.

Authors:  Shang Li; Hong Lu; Xiaofeng Hu; Wei Chen; Yingzhi Xu; Jing Wang
Journal:  Mediators Inflamm       Date:  2010-08-03       Impact factor: 4.711

4.  S100A8 promotes migration and infiltration of inflammatory cells in acute anterior uveitis.

Authors:  Yuqin Wang; Zuhui Zhang; Laihe Zhang; Xinxin Li; Rui Lu; Peipei Xu; Xuhong Zhang; Mali Dai; Xiaodan Dai; Jia Qu; Fan Lu; Zailong Chi
Journal:  Sci Rep       Date:  2016-10-27       Impact factor: 4.379

5.  Apremilast Regulates the Teff/Treg Balance to Ameliorate Uveitis via PI3K/AKT/FoxO1 Signaling Pathway.

Authors:  Yuxi Chen; Zhuang Li; He Li; Wenru Su; Yanyan Xie; Yuan Pan; Xiaoqing Chen; Dan Liang
Journal:  Front Immunol       Date:  2020-11-17       Impact factor: 7.561

Review 6.  New pharmacotherapy options for noninfectious posterior uveitis.

Authors:  Uwe Pleyer; Piergiorgio Neri; Christoph Deuter
Journal:  Int Ophthalmol       Date:  2021-02-25       Impact factor: 2.031

Review 7.  The cyclic AMP signaling pathway: Exploring targets for successful drug discovery (Review).

Authors:  Kuo Yan; Li-Na Gao; Yuan-Lu Cui; Yi Zhang; Xin Zhou
Journal:  Mol Med Rep       Date:  2016-03-18       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.